High frequency of level II-V lymph node involvement in RET/PTC positive papillary thyroid carcinoma

Eur J Surg Oncol. 2008 Jan;34(1):77-81. doi: 10.1016/j.ejso.2007.08.012. Epub 2007 Oct 22.

Abstract

Aims: To investigate the frequency and clinical significance of RET rearrangement in Chinese patients with papillary thyroid carcinoma (PTC) and discuss the role of RET rearrangement in therapeutic decision-making after the performance of level VI lymph node dissection and the 2002 AJCC staging system.

Methods: RET/PTC-1 and RET/PTC-3 were detected in 126 PTCs using reverse transcription-polymerase chain reaction (RT-PCR) and direct sequencing.

Results: RET rearrangement was detected in 18 cases of PTC. The patient group aged < 20 years had the highest frequency (3/6) of RET rearrangement among the age groups (< 20 years, 20-40 years and > or = 40 years; P=0.03). RET/PTC-1 positive patients were more likely to suffer from Hashimoto's thyroiditis simultaneously (P=0.02) while RET/PTC-3 positive patients had a higher frequency of extrathyroidal extension (P<0.01) and advanced T classification (P<0.01). RET rearrangement (OR=8.70, 95% CI 1.69-44.81), male (OR=3.88, 95% CI 1.41-10.69), age (OR=0.96, 95% CI 0.93-0.99), multifocality (OR=3.54, 95% CI 1.33-9.41) and advanced T classification (OR=7.32, 95% CI 2.91-18.40) were all identified as risk factors of level II-V lymph node involvement in the multivariate analysis.

Conclusions: The frequency of RET rearrangement in Chinese patients is low and age related. RET/PTC-1 and RET/PTC-3 are associated with different clinical pathological characteristics but not with lymph node involvement. The RET/PTC positive patients should receive more attention to lateral neck in the management of PTC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Carcinoma, Papillary / enzymology*
  • China
  • Female
  • Humans
  • Lymph Nodes / pathology*
  • Male
  • Oncogene Proteins, Fusion / genetics*
  • Protein-Tyrosine Kinases / genetics*
  • Risk Factors
  • Thyroid Neoplasms / enzymology*

Substances

  • Oncogene Proteins, Fusion
  • Protein-Tyrosine Kinases
  • ret-PTC fusion oncoproteins, human